Afinitor plus Somatuline significantly improved PFS in GEP-NETs compared to Afinitor monotherapy, with median PFS of 29.7 vs. 11.5 months. The combination therapy showed a higher objective response ...

Median PFS improved from 11.5 months with single-agent everolimus to 29.7 months with the addition of lanreotide. Objective responses occurred about three times as often with the combination.

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the ...

Objective Metabolic reprogramming plays a critical role in modulating the innate and adaptive immune response, but its role ...

Navigation Menu Toggle navigation Sign in Product ...

Pharmacokinetics is an area of pharmacology concerned with the time course of absorption, distribution, metabolism and excretion (collectively ADME) of drugs from biological systems in order to ...

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

WDHA syndrome was named for some of the characteristic symptoms of VIPoma: watery diarrhea, hypokalemia, and achlorhydria. Treatment Options for VIP-Associated Diarrhea and Flushing Patients with ...

The COP is the supreme decision-making body of the Convention. All States that are Parties to the Convention are represented at the COP, at which they review the implementation of the Convention and ...

The University of Oklahoma's $2.1 billion enterprise represents one of Oklahoma's greatest assets. Our impact is changing the lives of all Oklahomans, through scholarship, research and more. 30,000+ ...